Duloxetine reduced pain and improved function in patients with knee osteoarthritis, without causing X-ray abnormalities or altered knee joint mobility, according to a study published in the journal Dovepress.
Osteoarthritis (OA) is a common, chronic degenerative disease associated with cartilage degeneration and joint deformity that leads to pain and subsequent impairments in health-related quality of life (HRQoL). Knee OA, a very common form of OA, is a leading cause of disability worldwide
Yuji Uchio and his associates conducted a study to examine the efficacy and safety of duloxetine in patients with knee pain due to osteoarthritis.
A total of 354 patients included in the multicenter, randomized, placebo-controlled, double-blind study conducted at 47 medical institutions in Japan were randomized to receive duloxetine 60 mg/day or placebo for 14 weeks in a double-blind manner. The primary efficacy endpoint was the mean change in Brief Pain Inventory pain severity (BPI-Severity) average pain and secondary endpoints included improvement in other BPI-Severity scales.
Out of the 354 randomized patients, 161 in the duloxetine group and 162 in the placebo group completed the study.
The study found that:
- BPI-Severity average pain improved significantly with duloxetine vs. placebo (−2.57 vs. −1.80) at week 14.
- Compared with placebo, patients treated with duloxetine had significant improvements in all measures of pain, stiffness, and physical function (BPI-Severity, 24-hour BPI-Severity, WOMAC scores, and OMERACT-OARSI response rate)
- Adverse events observed in ≥5% of patients that were more frequent in the duloxetine than placebo group was somnolence, constipation, dry mouth, nausea, malaise, and decreased appetite.
- There were no marked changes in a range of motion of the knee joint (efficacy), X-ray images, or Kellgren–Lawrence grade (safety) in either group.
The study concluded that duloxetine showed superior clinical efficacy to placebo in pain reduction in patients with knee OA. The study revealed greater improvements in HRQoL in duloxetine-treated patients compared with placebo. The safety of duloxetine was consistent with its known safety profile. No marked changes were found in the joint structure on plain X-ray images in duloxetine-treated patients. Altogether, these findings suggest that duloxetine may be considered for the alleviation of pain in patients with pain due to knee OA.
For reference log on to https://doi.org/10.2147/JPR.S164128